Director / PDMR Shareholding

14^th Dec 2015

EKF Diagnostics Holdings plc (AIM: EKF), announces that it was informed on 11 December that Paul Foulger, who recently resigned from the Board as Finance Director and will leave the Company at the end of the year, had purchased 250,000 shares in EKF on that day at an average price of 11.56p.

Following this purchase Paul’s total shareholding is 3,738,589 ordinary shares, which represents 0.89% of the Company's issued share capital.

EKF Diagnostics Holdings plc Ron Zwanziger, Non-Executive Chairman Julian Baines, CEO	00 44 29 2071 0570 00 1 339 221 6282 00 44 7788 420 859
Panmure Gordon (UK) Limited Robert Naylor Paul Fincham	00 44 20 7886 2500
Walbrook PR Limited Paul McManus Lianne Cawthorne	00 44 20 7933 8780 or ekf@walbrookpr.com 00 44 7980 541 893 00 44 7584 391 303

Back to Listing

EKF Diagnostics

EKF Diagnostics Holdings plc is a manufacturer and distrbutor of IVD products. It has three core divisions: Point of Care including hemoglobin and HbA1c analyzers; Central Laboratory including the manufacture of enzymes and clinical chemistry; and Molecular Diagnostics which incorporates a unique DNA enrichment technology, PointMan, and a portfolio of molecular testing services.

News & events

Nurses from the University of Arkansas Study Abroad program using DiaSpect Tm in Ghana

EKF at Medic East Africa - Nairobi 2018

EKF to highlight new Glycated Albumin assay kit at AACC 2018

EKF Diagnostics, the global in vitro diagnostics company, announces that on Booth #3880 at the AACC 2018 Clinical Lab Expo it will be highlighting a new Stanbio Chemistry Glycated Albumin (GA) assay kit and its newly FDA cleared DiaSpect Tm hemoglobin point of care analyzer. Located in Chicago, IL, from July 31^st to August 2^nd, AACC is the world’s largest exposition for clinical laboratory products and services.